Status:
UNKNOWN
DNA Methylation in Allogeneic Hematopoietic Stem Cell Transplantation.
Lead Sponsor:
IRCCS Azienda Ospedaliero-Universitaria di Bologna
Collaborating Sponsors:
Mariarosaria Sessa, MD
Mario Arpinati, MD
Conditions:
Aging
Stem Cell Transplant Complications
Eligibility:
All Genders
18-70 years
Brief Summary
As a consequence of the impending increase in life expectancy, there is urgent need to adopt life-saving interventions, such as hematopoietic stem cell transplantation, (SCT) in groups of patients tha...
Detailed Description
The use of hematopoietic stem cell transplantation (SCT) in groups of patients previously unsuitable because of age is progressively increasing. Nowadays, allogeneic SCT in patients aged over 60 years...
Eligibility Criteria
Inclusion
- Patients aged ≥ 18.
- Patients with haematological disease undergoing allogeneic haematopoietic stem cell transplantation at "Seràgnoli" Hematology Institute, S. Orsola-Malpighi Hospital.
- Patients who consent to participate after signing written informed consent.
Exclusion
- \- Absence of written informed consent.
Key Trial Info
Start Date :
September 10 2018
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
September 10 2024
Estimated Enrollment :
50 Patients enrolled
Trial Details
Trial ID
NCT03871296
Start Date
September 10 2018
End Date
September 10 2024
Last Update
May 30 2023
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
St.Orsola-Malpighi University Hospital
Bologna, BO, Italy, 40138